Viome is a technology company specializing in advanced biological data analysis using AI and metatranscriptomic sequencing to provide personalized health insights, early disease detection, and nutrition recommendations. It serves consumers and researchers by analyzing gut microbiomes, gene expression, and microbial activity to address chronic diseases, cancer, and aging, aiming to make illness optional through precision health solutions[1][2][4].
Founded with a mission to digitize and decode human biology for prevention, early diagnosis, and treatment of chronic diseases and cancer, Viome leverages a proprietary AI platform called ViOS, which processes over 325,000 human samples to identify biomarkers and causal relationships in health and disease. Its products include at-home testing kits analyzing saliva, stool, and blood samples, combined with AI-driven personalized dietary and supplement recommendations, as well as FDA Breakthrough Device Designation for early oral and throat cancer detection[1][2][5].
---
Viome was founded by Naveen Jain, a serial entrepreneur with a background in technology and innovation, driven by the vision to transform healthcare by making illness optional through early detection and personalized interventions. The idea emerged from the recognition that chronic diseases and cancer could be better managed or prevented by understanding the complex interactions between human gene expression and the microbiome. Early traction came from developing predictive models for diseases like diabetes, obesity, depression, and cancer, supported by collaborations with scientific and technology leaders, and venture backing from firms like Khosla Ventures[1][2][4].
---
---
Viome rides the growing trend of personalized medicine, leveraging AI and big data to move beyond descriptive microbiome studies toward actionable, causative health insights. The timing is critical as chronic diseases and cancer remain leading causes of death globally, and there is increasing demand for early detection and prevention tools. Market forces such as advances in sequencing technology, AI, and consumer interest in personalized health solutions favor Viome’s approach. By integrating multi-omics data and AI, Viome influences the broader ecosystem by setting new standards for precision diagnostics and nutrition, fostering collaboration between biotech, AI, and healthcare sectors[1][2][4].
---
Viome is positioned to expand its impact by scaling early disease detection technologies and broadening its personalized health offerings. Future trends shaping its journey include deeper integration of multi-omics data, AI advancements, and growing regulatory acceptance of AI-driven diagnostics. As Viome continues to refine its AI models and expand its dataset, it may evolve from a consumer health company into a critical player in clinical diagnostics and therapeutics, potentially transforming how chronic diseases and cancer are managed globally. Its mission to make illness optional remains a compelling vision that aligns with the increasing shift toward preventive and personalized healthcare[1][2][4].
Viome has raised $279.0M in total across 7 funding rounds.
Viome's investors include Alumni Ventures, Amazon Climate Pledge Fund, Prime Movers Lab, Alliance of Angels, Bold Capital Partners, Alan Cohen, Khosla Ventures, Recode Ventures, SOSV, Marc Benioff.
Viome has raised $279.0M across 7 funding rounds. Most recently, it raised $25.0M Series D in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $25.0M Series D | Alumni Ventures, Amazon Climate Pledge Fund, Prime Movers Lab | |
| Aug 1, 2023 | $87.0M Series C | Alliance of Angels, Bold Capital Partners, Alan Cohen, Khosla Ventures, Recode Ventures, SOSV, Marc Benioff | |
| Oct 1, 2022 | $67.0M Series C | Bold Capital Partners, Alan Cohen, Khosla Ventures, Recode Ventures, SOSV | |
| Nov 1, 2021 | $54.0M Series C | Khosla Ventures, SOSV | |
| Apr 1, 2019 | $25.0M Series B | Alumni Ventures, Amazon Climate Pledge Fund, Prime Movers Lab | |
| Jul 1, 2018 | $6.0M Series B | Khosla Ventures, SOSV | |
| Jul 1, 2017 | $15.0M Series A | Khosla Ventures, SOSV |
